tiprankstipranks
Trending News
More News >
BridgeBio Oncology Therapeutics (BBOT)
NASDAQ:BBOT
US Market
Advertisement

BridgeBio Oncology Therapeutics (BBOT) Ownership - Who Owns BridgeBio Oncology Therapeutics?

Compare
15 Followers

Recent Insider Trading Activity

Date
Name
Activity
Value

Recent Hedge Fund Trading Activity

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
17,878,594Insider22.35%221,515,780
14,589,846Insider18.24%180,768,192
4,885,446Institution6.11%60,530,676
3,289,661Institution4.11%40,758,900
841,293Institution1.05%10,423,620
600,000Institution0.75%7,434,000
564,625Institution0.71%6,995,704
509,000Insider0.64%6,306,510
506,514Institution0.63%6,275,708
398,000Institution0.50%4,931,220

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
841,293Institution1.05%10,423,620
13,328Institution0.02%165,134

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
506,514Institution0.63%6,047,777
228,650Institution0.29%2,784,957
27,500Institution0.03%334,950

FAQ

Who Owns BridgeBio Oncology Therapeutics (BBOT)?
Currently, no data Available
What percentage of BridgeBio Oncology Therapeutics (BBOT) stock is held by institutional investors?
Currently, no data Available
What percentage of BridgeBio Oncology Therapeutics (BBOT) stock is held by retail investors?
Currently, no data Available
Who owns the most shares of BridgeBio Oncology Therapeutics (BBOT)?
Bihua Chen owns the most shares of BridgeBio Oncology Therapeutics (BBOT).
    What is the significance of the ownership structure for a publicly traded company?
    The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
      What am I Missing?
      Make informed decisions based on Top Analysts' activity
      Know what industry insiders are buying
      Get actionable alerts from top Wall Street Analysts
      Find out before anyone else which stock is going to shoot up
      Get powerful stock screeners & detailed portfolio analysis